Persistent Corneal Epithelial Defect
Ophthalmology
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Glaukoslufepirsen high dose
SantenDE-105 ophthalmic solution
Clinical Trials (2)
Total enrollment: 45 patients across 2 trials
A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED
Start: Aug 2023Est. completion: Dec 2025
Phase 2Recruiting
Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect
Start: Sep 200945 patients
Phase 2Completed
Related Jobs in Ophthalmology
Lead Data Manager
Genomics
Remote
8h ago
Cleanroom and Laboratory Technician
SAB BIO
8h ago
APAC Regulatory Affairs Manager
Johnson & Johnson
Singapore, Singapore
Yesterday
Clinical Operations Manager
Johnson & Johnson
Irvine, California, United States of America
Yesterday
$117K - $201K/yr
Site Delivery Leader MLL
Johnson & Johnson
Gent, East Flanders, Belgium
Yesterday
BM 喀什 PSR HY
Johnson & Johnson
Urumqi, Xinjiang, China
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 45 patients
2 companies competing in this space